Ads
HomeFinanceFDA approves Innoviva’s bacterial pneumonia treatment

FDA approves Innoviva’s bacterial pneumonia treatment

[ad_1]

The Food and Drug Administration said Tuesday that it approved Innoviva’s
INVA,
-0.73%

Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

The federal regulator said Xacduro, which treats ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia, is hard to treat and poses a great threat to human health.

The FDA granted approval of Xacduro, administered by intravenous infusion, to Entasis Therapeutics, acquired by the pharma company Innoviva last year.

[ad_2]

Source link

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments